Shelby Anderson, Chief Scientific Officer, Presents Poster
From July 9th to12th, AIT Bioscience’s Chief Scientific Officer, Shelby Anderson, Ph.D., attended the 2018 Land O’ Lakes Bioanalytical Conference in Madison, Wisconsin. The three-day conference encourages an open exchange of scientific and methodological applications for bioanalysis.
During the conference, AIT Bioscience presented a poster on the development of an LC-MS/MS method to quantitate Colistin and Colistimethate in human plasma. The method was developed to support pharmacokinetic analysis for TEVA Pharmaceuticals.
Each year at this conference, FDA regulators provide presentations, conversations and guidance about relevant drug development industry changes. This year’s presentation included insights into the new Bioanalytical Method Validation Guidance issued by the FDA in May.
The theme for this year’s conference was “Emerging Therapeutic Paradigms: Supporting the Next Generation of Biomarker and Bioanalytical Research.” As a result, there was an emphasis on large molecule proteins and biologic therapeutics (gene therapy and cell-based therapies) throughout the event. Another topic of interest was the increasing role that quantitation of biomarkers is playing in drug development. These topics align with AIT Bioscience’s on-going efforts to expand our large molecule and biomarker support services. With the recent addition of our Vice President of Scientific Services, Ligand Binding Assays (LBA), Mark Cameron, AIT Bioscience is focused on meeting our sponsors’ needs in existing as well as emerging therapeutic paradigms.